Kintara Therapeutics to Present at the 2nd Annual Glioblastoma Drug Development Summit December 3, 2020 • 8:30 AM EST
Kintara Therapeutics Reports 10 Months Progression-Free Survival in Newly-Diagnosed MGMT-unmethylated GBM from Ongoing MD Anderson Cancer Center Phase 2 Study November 19, 2020 • 8:00 AM EST
Kintara Therapeutics Announces First Fiscal Quarter 2021 Financial Results and Recent Corporate Updates November 13, 2020 • 8:00 AM EST
Kintara and the Global Coalition for Adaptive Research Execute Agreement for VAL-083's Participation in the GBM AGILE Registrational Study October 21, 2020 • 8:00 AM EDT
Kintara Therapeutics Announces Fiscal Year 2020 Financial Results and Recent Corporate Updates September 21, 2020 • 8:30 AM EDT
Kintara Therapeutics Completes Final Closing of Previously Announced Private Placement For an Aggregate of $25 Million September 1, 2020 • 8:30 AM EDT
Kintara Therapeutics (formerly DelMar Pharmaceuticals) to Present at the LD Micro 500 Virtual Conference on September 3rd, 2020 August 26, 2020 • 8:30 AM EDT
Kintara Therapeutics Announces Closing of Additional $2.2 Million Private Placement Priced at the Market August 25, 2020 • 8:30 AM EDT
Kintara Therapeutics Announces Additional $2.4 Million Private Placement Priced At-The-Market August 21, 2020 • 8:15 AM EDT
Kintara Therapeutics (formerly DelMar Pharmaceuticals) Regains Compliance with NASDAQ Minimum Bid Price Requirement August 21, 2020 • 8:00 AM EDT